IF at the end of the day (whatever day THAT is), all we could look forward to was getting this "drug" over the finish line for one single, solitary purpose, all the hyperbolic hand wringing over dilution would mean much more to me than it currently does.
Everything we can glean from the last several announcements, press releases, and filings, tells me that there are at the very least 4-6 very real chances for success in trials and submissions over the next 3-6 months. It will be absolutely necessary to get one, probably two of them across the finish line to provide revenue enough to forestall managements' need to use some or a good portion of the 200 million shares we are being asked to vote on very soon.
IF, we do not approve these additional shares, we will hobble our company and doom it to an all or nothing gamble on getting that single, solitary approval before current cash is depleted.
There is a current running through several boards right now that is urging us to deny our company these additional bullets for our guns. They want us to look back at all the money spent and say "Enough is Enough". The proposition is that management could have spent previous sums far more effectively, far more judiciously.
Hindsight is most valuable in reconciliation for future planning of like kind endeavors and forensic analysis to track what actually happened versus what was forecast. WHEN we see multiple approvals and are having to vote on partnerships with Big Pharma on a per indication basis, we absolutely NOT sweat whether we have 800 million or one billion shares outstanding.
Be real, be honest with yourself, if we NEVER got an approval, got no acceptable offer to purchase our IT, how many would really care that we held our ground at 800 millions shares?
Everything we can glean from the last several announcements, press releases, and filings, tells me that there are at the very least 4-6 very real chances for success in trials and submissions over the next 3-6 months. It will be absolutely necessary to get one, probably two of them across the finish line to provide revenue enough to forestall managements' need to use some or a good portion of the 200 million shares we are being asked to vote on very soon.
IF, we do not approve these additional shares, we will hobble our company and doom it to an all or nothing gamble on getting that single, solitary approval before current cash is depleted.
There is a current running through several boards right now that is urging us to deny our company these additional bullets for our guns. They want us to look back at all the money spent and say "Enough is Enough". The proposition is that management could have spent previous sums far more effectively, far more judiciously.
Hindsight is most valuable in reconciliation for future planning of like kind endeavors and forensic analysis to track what actually happened versus what was forecast. WHEN we see multiple approvals and are having to vote on partnerships with Big Pharma on a per indication basis, we absolutely NOT sweat whether we have 800 million or one billion shares outstanding.
Be real, be honest with yourself, if we NEVER got an approval, got no acceptable offer to purchase our IT, how many would really care that we held our ground at 800 millions shares?
16
